HealthDay News -- Screening Medicare beneficiaries for colorectal cancer (CRC) using stool DNA testing is not currently cost-effective, but could be if the cost per test dropped dramatically or if adherence to the testing were substantially better than for other screening tests, according to an analysis published in the Sept. 21 issue of the Annals of Internal Medicine.
